Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKTXNASDAQ:ATHENASDAQ:BRNSOTCMKTS:CUBT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKTXAkari Therapeutics$1.18+2.2%$1.27$0.85▼$4.40$37.97M0.2131,403 shs2,252 shsATHEAlterity Therapeutics$4.04-0.1%$4.22$1.00▼$5.87$35.79M0.71145,217 shs11,274 shsBRNSBarinthus Biotherapeutics$0.98+3.1%$0.93$0.64▼$1.58$39.33M-0.835,532 shs16,172 shsCUBTCurative Biotechnology$0.01-14.4%$0.01$0.00▼$0.03$9.62M0.35155,331 shs1.04 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKTXAkari Therapeutics0.00%+1.80%-8.17%+7.27%-58.89%ATHEAlterity Therapeutics0.00%+2.67%-14.69%+46.20%+120.81%BRNSBarinthus Biotherapeutics0.00%+4.84%-2.01%+40.49%-30.60%CUBTCurative Biotechnology0.00%-3.06%-20.17%-13.64%-52.26%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKTXAkari Therapeutics1.5335 of 5 stars0.05.00.00.01.83.30.0ATHEAlterity Therapeutics2.6344 of 5 stars3.35.00.00.00.01.70.0BRNSBarinthus Biotherapeutics2.5598 of 5 stars3.55.00.00.00.00.01.3CUBTCurative BiotechnologyN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKTXAkari Therapeutics 0.00N/AN/AN/AATHEAlterity Therapeutics 2.50Moderate Buy$12.00197.40% UpsideBRNSBarinthus Biotherapeutics 3.00Buy$6.25541.03% UpsideCUBTCurative Biotechnology 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKTXAkari TherapeuticsN/AN/AN/AN/A$0.84 per shareN/AATHEAlterity TherapeuticsN/AN/AN/AN/A$1.04 per shareN/ABRNSBarinthus Biotherapeutics$14.97M2.63N/AN/A$3.23 per share0.30CUBTCurative BiotechnologyN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKTXAkari Therapeutics-$19.79MN/A0.00∞N/AN/A-213.59%-65.60%8/18/2025 (Estimated)ATHEAlterity Therapeutics-$12.54MN/A0.00∞N/AN/AN/AN/A8/4/2025 (Estimated)BRNSBarinthus Biotherapeutics-$61.07M-$1.64N/AN/AN/AN/A-46.43%-38.50%8/6/2025 (Estimated)CUBTCurative BiotechnologyN/AN/A0.00∞N/AN/AN/AN/AN/ALatest CUBT, AKTX, BRNS, and ATHE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025BRNSBarinthus Biotherapeutics-$0.34-$0.49-$0.15-$0.49N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKTXAkari TherapeuticsN/AN/AN/AN/AN/AATHEAlterity TherapeuticsN/AN/AN/AN/AN/ABRNSBarinthus BiotherapeuticsN/AN/AN/AN/AN/ACUBTCurative BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKTXAkari TherapeuticsN/A0.160.16ATHEAlterity TherapeuticsN/A3.84N/ABRNSBarinthus BiotherapeuticsN/A9.189.18CUBTCurative BiotechnologyN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKTXAkari Therapeutics5.06%ATHEAlterity Therapeutics2.14%BRNSBarinthus Biotherapeutics25.20%CUBTCurative BiotechnologyN/AInsider OwnershipCompanyInsider OwnershipAKTXAkari Therapeutics38.10%ATHEAlterity Therapeutics38.80%BRNSBarinthus Biotherapeutics8.00%CUBTCurative BiotechnologyN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKTXAkari Therapeutics932.18 million19.92 millionNot OptionableATHEAlterity Therapeutics108.87 million5.43 millionNot OptionableBRNSBarinthus Biotherapeutics10740.34 million37.11 millionN/ACUBTCurative BiotechnologyN/A1.01 billionN/ANot OptionableCUBT, AKTX, BRNS, and ATHE HeadlinesRecent News About These CompaniesCurative Biotechnology, Inc. (CUBT) - Yahoo FinanceJuly 2, 2025 | finance.yahoo.comCurative Biotechnology, Inc. Engages Golden Eagle Capital Advisors, Inc. as Exclusive Agent and Strategic AdvisorDecember 13, 2024 | globenewswire.comZacks Dividend Fund Institutional Class Shares (ZDIIX) Stock Price, Quote, News & Analysis - Seeking AlphaJuly 20, 2024 | seekingalpha.comExcision’s CRISPR-Based HIV Treatment Fails to Show Curative Potential in Early StudyMay 13, 2024 | biospace.comBPsychological Safety in Today’s Global WorkforceApril 4, 2024 | medindia.netMMedcura Closes $22.4 Million Financing to Accelerate Development of Surgical Hemostatic Gel and Surgical Hemostasis PortfolioApril 4, 2024 | medindia.netMNew, Fast-Acting, Conservative Treatment Reverses ScoliosisApril 4, 2024 | medindia.netMCurative Biotechnology, Inc. Announces Nomination of Dr. Theresa Heah to Board of DirectorsMarch 31, 2024 | globenewswire.comSFRX Seafarer Exploration Corp.March 29, 2024 | seekingalpha.comCurative Biotechnology, Inc. Announces Nomination of Dr. Theresa Heah to Board of DirectorsMarch 22, 2024 | globenewswire.comShould You Expect Strong Financial Growth For Legend Biotech Corporation (LEGN)?January 22, 2024 | insidermonkey.comJPM24: Biotech investors tip toe around the bear market to familiar territoryJanuary 16, 2024 | fiercebiotech.comFCurative Biotechnology, Inc.?: Curative Biotechnology, Inc. Announces Nomination of Dr. Jeffrey Liebmann to Board of DirectorsOctober 31, 2023 | finanznachrichten.de3 Best Biotech Stocks to Add to Your PortfolioAugust 18, 2023 | thestreet.comCurative Biotechnology Announces Establishment of Japanese Subsidiary for Licensing Transactions and Asset AcquisitionsJune 6, 2023 | finance.yahoo.comSacramento Biotech NewsJune 2, 2023 | bizjournals.comCurative Biotechnology, Inc. Files Patent on Ophthalmic FormulationMay 24, 2023 | finance.yahoo.comIs Curative Biotechnology Inc (CUBT) Stock a Good Investment?March 10, 2023 | aaii.comACurative Biotechnology, Inc.?: Curative Biotechnology Announces Completion of IND Enabling Reformulated Metformin HCL Eye Drop StudyJanuary 5, 2023 | finanznachrichten.deCurative Biotechnology, Inc. (CUBT)November 12, 2022 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCUBT, AKTX, BRNS, and ATHE Company DescriptionsAkari Therapeutics NASDAQ:AKTX$1.18 +0.03 (+2.16%) As of 07/3/2025 01:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.Alterity Therapeutics NASDAQ:ATHE$4.04 -0.01 (-0.12%) Closing price 07/3/2025 01:19 PM EasternExtended Trading$4.02 -0.02 (-0.47%) As of 07/3/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.Barinthus Biotherapeutics NASDAQ:BRNS$0.98 +0.03 (+3.07%) Closing price 07/3/2025 01:46 PM EasternExtended Trading$0.98 0.00 (0.00%) As of 07/3/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.Curative Biotechnology OTCMKTS:CUBT$0.0095 0.00 (-14.41%) As of 07/3/2025 12:52 PM EasternCurative Biotechnology, Inc., a development-stage biomedical company, focuses on novel treatments for rare diseases. The company focuses on therapies with potentially accelerated development paths as a result of the disease, the nature of the therapeutic itself, or the stage of clinical development. Its pipeline candidates include CURB906, an antibody-drug conjugate for targeting CD56 positive brain tumors; and IMT504, a novel immune therapy to treat rabies. The company has an agreement with Mid-Atlantic BioTherapeutics, Inc. to develop the COVID-19 vaccine. Curative Biotechnology, Inc. was founded in 1995 and is based in Boca Raton, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Correction Equals Opportunity in Domino’s Pizza Stock Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
